Abstract
The purpose of the study. The achievedheart rate of 50-60 beats per minute in patients after acute myocardial infarction, and up to50-70 beats per minute for patients with stable angina is considered effective. Assuming that in Russia low doses of β-blockers are often used, thequestion was raised: «How common tachycardia can bein patients with coronary heart disease (CHD) and chronic heart failure (CHF), and whether there are strategic approaches to achieving the targets in heart rate in these patients in real clinical practice and are β-blockers often used in patients for whom this group of drugs is the basic one?»Materials and Methods. Work carried out in the framework of the Russian epidemiological study of a representative sample of the European partof the Russian Federation. All patients with CHF and coronary artery disease were divided into two subgroups: heart rate reducers not receiving medicines and receiving at least one heart rate reducing drug (a β-blocker, calcium channel 1 and 3rd type (AK) blockers, glycosides).Results and discussion. In a representative sample of the program in healthy individuals (without clinical manifestations of coronary arterydisease) tachycardia was diagnosed in 7,1% of cases. Almost all respondents without CHD (87,3%) had normal heart rate from 61 to 80 beats per minute. Number of respondents without CHD with heart rate of 70 to 79 bpm. per min. (54,1%) turned out to be significantly less than that of patients with rhythm in any form of coronary artery disease (p
Highlights
Бзоры β-Blockers: the lack of taskimplementation or the unwillingness of doctors in the Russian Federation to optimize the treatment? I.V.Fomin, D.S.Polyakov
All patients with chronic heart failure (CHF) and coronary artery disease were divided into two subgroups: heart rate reducers not receiving medicines and receiving at least one heart rate reducing drug (a β-blocker, calcium channel 1 and 3rd type (AK) blockers, glycosides)
In a representative sample of the program in healthy individuals tachycardia was diagnosed in 7,1% of cases
Summary
И.В.Фомин, Д.С.Поляков ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России. Answering the question posed in the title, you can say: doctors are not ready to take an active position in prescribing and achievingthe target doses of β-blockers This situation immediately generates the lack of task implementation in terms of optimization of therapy and reduces the risk of cardiovascular mortality in coronary artery disease and heart failure. Предполагая, что в РФ нередко используют низкие дозы β-адреноблокаторов (β-АБ) [15], напрашивается вопрос, насколько часто встречается тахикардия среди больных с ИБС и ХСН, существуют ли стратегические подходы к достижению целевых показателей ЧСС у данной категории пациентов в реальной клинической практике и как часто используются β-АБ в лечении пациентов, для которых эта группа лекарственных препаратов представляет собой базисные средства?. В исследовании «ЭПОХА» тахикардия определялась среди здоровых респондентов как ЧСС>80 уд/мин, а для больных с ХСН и ИБС – более 70 уд/мин. По сравнению с другими антигипертензивными средствами β-АБ более эффективны в профилактике кардиоваскулярных осложнений у пациентов с ХСН или после перенесенного ОИМ [20]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
